Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

Åke Hjalmarson, MD, PhD Sidney Goldstein, MD Björn Fagerberg, MD, PhD Hans Wedel, PhD Finn Waagstein, MD, PhD John Kjekshus, MD, PhD John Wikstrand, MD, PhD Dia El Allaf, MD Jirı́ Vı́tovec, MD, PhD Jan Aldershvile, MD, PhD Matti Halinen, MD, PhD Rainer Dietz, MD Karl-Ludwig Neuhaus, MD András Jánosi, MD, DSc Gudmundur Thorgeirsson, MD, PhD Peter H. J. M. Dunselman, MD, PhD Lars Gullestad, MD Jerzy Kuch, MD Johan Herlitz, MD, PhD Peter Rickenbacher, MD Stephen Ball, MD, PhD Stephen Gottlieb, MD Prakash Deedwania, MD for the MERIT-HF Study Group

[1]  K. Bailey,et al.  Congestive heart failure in the community: trends in incidence and survival in a 10-year period. , 1999, Archives of internal medicine.

[2]  A. Hall,et al.  Mode of death in chronic heart failure. A request and proposition for more accurate classification. , 1996, European heart journal.

[3]  J. Herlitz Rationale, design, and organisation of the metoprolol CR/XL randomized trial in heart failure (MERIT-HF) , 1997 .

[4]  T. Hedner,et al.  Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. , 1991, Journal of the American College of Cardiology.

[5]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[6]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[7]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[8]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[9]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[10]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[11]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[12]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[13]  J. Cohn,et al.  Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. , 1992, American heart journal.

[14]  B. Andersson 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial , 1998, The Lancet.

[15]  Y Wang,et al.  Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.

[16]  D A Bloch,et al.  Capturing the patient's view of change as a clinical outcome measure. , 1999, JAMA.